These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7483058)

  • 1. [Hepatorenal syndrome].
    Petersen JS
    Ugeskr Laeger; 1995 Sep; 157(39):5405-7. PubMed ID: 7483058
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of somatostatin and its long-acting analogue, octreotide, in the treatment of pancreatic diseases.
    Delmont J; Hastier P; Dumas R
    Aliment Pharmacol Ther; 1995 Oct; 9(5):581-3. PubMed ID: 8580282
    [No Abstract]   [Full Text] [Related]  

  • 3. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 4. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients.
    Kaffy F; Borderie C; Chagneau C; Ripault MP; Larzillière I; Silvain C; Beauchant M
    J Hepatol; 1999 Jan; 30(1):174. PubMed ID: 9927168
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathophysiology of the hepatorenal syndrome and potential for therapy.
    Levy M
    Am J Cardiol; 1987 Dec; 60(17):66I-72I. PubMed ID: 3687808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C; Einstein M; Lucey MR; Said A
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatorenal syndrome].
    Epstein M
    Rev Clin Esp; 1988 Jun; 183(1):37-41. PubMed ID: 2972019
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hepatorenal syndrome: pathogenesis and treatment].
    Ashkenazi E; Ilan Y; Shoval D
    Harefuah; 2007 Jun; 146(6):475-9, 499. PubMed ID: 17760404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatorenal syndrome: a dreaded complication of end-stage liver disease.
    Cárdenas A
    Am J Gastroenterol; 2005 Feb; 100(2):460-7. PubMed ID: 15667508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatorenal syndrome: definition, pathophysiology, clinical features and management.
    Bataller R; Sort P; Ginès P; Arroyo V
    Kidney Int Suppl; 1998 May; 66():S47-53. PubMed ID: 9573573
    [No Abstract]   [Full Text] [Related]  

  • 12. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 13. Possible increased risk of pulmonary edema in patients with hepatorenal syndrome on adding octreotide to albumin / noradrenaline therapies.
    Abutaleb N
    Saudi J Kidney Dis Transpl; 2007 Jun; 18(2):261. PubMed ID: 17496406
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases].
    Feu F; Bosch J
    Gastroenterol Hepatol; 1996 Feb; 19(2):68-77. PubMed ID: 8616683
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
    Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
    Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome.
    Møller S; Bendtsen F; Henriksen JH
    Scand J Gastroenterol; 2005 May; 40(5):491-500. PubMed ID: 16036500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma.
    Morris DL
    Cancer; 1996 May; 77(9):1956-7. PubMed ID: 8646698
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
    Arroyo V; Ginès P; Gerbes AL; Dudley FJ; Gentilini P; Laffi G; Reynolds TB; Ring-Larsen H; Schölmerich J
    Hepatology; 1996 Jan; 23(1):164-76. PubMed ID: 8550036
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.